Progress in the treatment paradigms for locally advanced cervical cancer

Mené sur 500 patientes atteintes d'un cancer du col de l'utérus localement avancé (durée médiane de suivi : 67 mois), cet essai randomisé international de phase III évalue l'intérêt, du point de vue de la survie sans progression et de la survie globale, d'ajouter une chimiothérapie d'induction à une chimioradiothérapie standard à base de cisplatine

Résumé en anglais

Locally advanced cervical cancer remains a substantial source of mortality, particularly in low-resource settings. Once-a-week cisplatin with external beam radiation followed by intracavitary or interstitial brachytherapy was established in 1999 as the standard of care and has not been altered by four large, international trials or by previous neoadjuvant chemotherapy trials. The first published definitively positive trial since 1999, the KEYNOTE-A18 study, showed improved progression-free survival and overall survival with the addition of pembrolizumab during and after chemoradiotherapy for those with International Federation of Gynecology and Obstetrics (FIGO) 2014 stage IB2–IIB with any pelvic nodal metastases and III–IVA regardless of nodal status.